Stephanie Anderson is an Associate Director of Regulatory Affairs at Intrinsik Corp. She has been a part of the pharmaceutical/biotechnology sector since 2010 and now leads a dedicated team of Regulatory Affairs professionals. Stephanie has led a broad range of regulatory activities from clinical development to post-registration license maintenance across a wide range products and therapeutic areas. Stephanie has experience with FDA, Health Canada, EMA, BfArM, and MHRA. Stephanie has a Master of Science degree in Biochemistry and Physiology from the University of Western Ontario.

Mei Lam is the Pharmacovigilance Manager for Haleon Canada. She has over 15 years in industry, primarily in Pharmacovigilance (PV). In addition to PV, Mei has experience in medical information, medical affairs, and global deviation management. Mei is a registered Nurse in Ontario who volunteers for the Region of Peel Public Health Unit.

Dr. Yatika Kohli is an accomplished Senior Regulatory Professional with strong leadership skills, strategic foresight and business acumen. At NoNO Inc, Dr. Kohli is leading all strategic and global regulatory initiatives for NoNO’s products. With more than 20 years of experience in Biotech/Pharmaceutical industry, Dr. Kohli has expertise in developing global regulatory and clinical strategy with project and product management across multiple modalities and jurisdictions. She led the regulatory activities for the registration and launch of two blockbuster vaccines for Sanofi Pasteur in the USA and Apotex’s first biosimilar product in Europe.

Katalin Bertenyi is the manager of the Clinical Evaluation Division - Endocrine and Metabolic Diseases, situated in CBBB in the Biologic and Radiopharmaceutical Drugs Directorate of Health Canada. Her team is responsible for the evaluation of biologics for endocrine and metabolic diseases, including rare diseases. She has over 20 years of experience with Health Canada, in the clinical evaluation of biologic and pharmaceutical drugs in the areas of reproduction, urology, oncology, endocrinology and metabolism, as well as experience in regulatory affairs, and clinical trials for medical devices and pharmaceutical drugs. Katalin holds a B.Sc. (Honours) in Biotechnology/Biology and a M.Sc. in Biology, both from Carleton University in Ottawa.

Dr Hocine Abid is an international medical doctor graduate. Hocine also holds an MBA from École des Hautes Études Commerciales (École des HEC Montréal) and a Graduate Diploma in public administration from École Nationale d’Administration Publique. Hocine is the national manager for Health Canada’s Clinical Trial Compliance Program that oversees the inspections of clinical trials since 2018. Before this, he occupied different roles in various positions within Health Canada such as manager of the GMP inspection program, and Head of the medical cannabis program overseeing the evaluation and the delivery of authorizations to possess and produce cannabis for medical purposes.

Anna Bussel is a pharmaceutical professional with 15+ years of experience in pharmacovigilance (PV), regulatory affairs (RA), and quality assurance (QA). Her career spans both the pharmaceutical industry—holding PV, RA, and QA roles at Eli Lilly and Company—and consulting, where she headed the PV & MI Department at Veristat, Science-First™ CRO, providing strategic PV & MI advice to multiple clients. She has led numerous GVP and GMP audits on behalf of Marketing Authorisation Holders and liaised with Health Authorities on market access and drug policy improvements. Anna holds a Master’s in Pharmacy and is an active member of the DIA.

Daniel Greco is the Associate Director of Patient Safety at Bristol Myers Squibb, with a specialization in Risk Management. In this capacity, Daniel has led substantial changes to the risk management program responsible for overseeing the risks associated with thalidomide and its derivatives in Canada. He earned his H.BSc. and PharmD from the University of Toronto, and is presently pursuing a Masters in Pharmacovigilance and Pharmacoepidemiology through the Eu2P program. Moreover, Daniel is practicing as a licensed Pharmacist in the province of Ontario, where he has gained invaluable firsthand experience in direct patient care.

Ricardo works as a Safety Team Lead at Pfizer Drug Safety Unit Canada and has been with the company since 2022. He has been working in the industry for 14 years in the Montreal area. A couple of years after graduating as a Physician in Peru, Ricardo moved to Canada and started working in Pharmacovigilance and Medical Information to later focus on his new passion, Pharmacovigilance and Drug Safety. He has completed different Pharmacovigilance trainings including the PV course by Kusuri Canada Corp., GVP course at Cegep Gerald Godin in Montreal and Preclinical Safety Assessment and Pharmacovigilance given by the Uppsala University.

Riti Singh is a dynamic and strategic, transformational leader, accomplished in building departments from inception and transforming them into high performing, value-added, revenue generating functions. With over 20 years of broad therapeutic experience in the life sciences and healthcare sector, she has expertise in setting up pharmacovigilance, medical information, medical affairs, and quality operations for local and global organizations. Riti holds a PharmD degree from Leslie Dan Faculty of Pharmacy at University of Toronto and an MBA from California State University. Currently at Bayshore, Riti is the National Director overseeing Clinical Trials, RWE, Pharmacovigilance, Medical Information, Quality and Regulatory DEL/MDEL activities.

Yulia is a Scientific Evaluator at the Marketed Pharmaceuticals Bureau (MPB), Health Canada, where she focuses on drug safety. Prior to this role, she conducted research in genome stability and cell signaling at Université de Sherbrooke and McGill University, and later supported global clinical and regulatory strategies at Allucent. With over 15 years of experience in academia, industry, and government sectors, spanning fundamental and biomedical research, clinical trials and regulatory affairs, she brings a broad expertise across the drug development life cycle. Yulia holds a PhD degree in Cell and Molecular Biology from the University of Edinburgh, UK and RAPS Regulatory Affairs Certification (RAC-Drugs).

Adesola Adeyemi has been with Bayer Inc. since 2019 with the Regulatory Affairs team. Adesola has worked on various regulatory submissions for human and animal drug products during her career at Bayer Inc. Adesola has a Master of Science degree in Drug Design, a Bachelor of Science in Chemistry/Industrial Chemistry and a Post-graduate diploma in Regulatory Affairs.

Oxana Iliach, PhD is a Sr. Director, Regulatory Strategy and Policy at Certara/Synchrogenix. She has more than 15 years of experience in the healthcare industry including the last 10+ years in regulatory affairs. Her specialty is developing and executing regulatory strategies for drugs for rare diseases, pediatrics, advanced therapy products and biosimilars, with a focus on Chemistry, Manufacturing and Control (CMC). Oxana has experience with the FDA, EMA, Health Canada, and other smaller agencies. She is also a part-time lecturer at Northeastern University, Toronto campus and professor at Seneca College of Applied Arts and Technology. Oxana is a member of CAPRA, RAPS, CORD and IRDiRC.